Skip to main content
. Author manuscript; available in PMC: 2017 Sep 1.
Published in final edited form as: Am J Transplant. 2016 Apr 22;16(9):2532–2544. doi: 10.1111/ajt.13765

TABLE 4.

RANDOMIZED TRIALS OF CALCINEURIN-INHIBITOR MINIMIZATION STUDIES AFTER THE FIRST YEAR POST- LIVER TRANSPLANTATION

AUTHOR N STUDY DESIGN MAJOR FINDINGS
Abdelmalek (71) 607 Month 6–144: CNI to SRL vs. CNI continuation

  • No improvement in GFR with SRL conversion

  • Higher AR rates with SRL conversion
De Simone (66) 145 Prospective randomized controlled:
EVR + low dose CNI/CNI elimination vs. standard dose CNI × 6 months, GFR 20–60 at enrollment
Time from LT to enrollment: 12–60 months

  • No difference in eGFR or AR in both groups
Pageaux (68) 56 Prospective randomized controlled:
MMF + low dose CNI vs. standard CNI for chronic renal failure
Time from LT to enrollment: 1 year post-LT

  • Significant improvement in eGFR in MMF+ low dose CNI at 1 year

  • No AR in either group
Beckebaum (63) 90 Prospective randomized controlled (2:1):
MMF + low dose CNI vs. standard CNI for SCr>1.2 mg/dl
Time from LT to enrollment: 1 year post-LT

  • Significant improvement in eGFR in MMF+ low dose CNI at 1 year

  • No AR in either group

CNI, calcineurin inhibitor; eGFR, estimated glomerular filtration rate; SCr, serum creatinine; SRL, sirolimus.